SUPRIYA · NSE
Supriya Lifescience Limited
₹620.15
-0.78% (-₹4.85)
Prev. close
₹625
Volume
1,32,451
Delivery %
53.7%
As of
20 Nov 2026
Price history
Analyst sentiment
No analyst stances in this range
0 analyst stances · last 90 days · one per analyst
Try a wider range.
Explore by date range →Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Recommends buying Supriya Lifescience at ₹802 with a target of ₹865 and a stop loss at ₹770, based on a breakout stock s…” | Sumeet BagadiaChoice Equity Broking | Supriya Lifescience Ltd | NOT TRIGGERED | |
| “Recommends accumulating Supriya Lifescience with a target of ₹850. The call implies a bullish outlook on the stock.” | Deven ChokseyIndependent | Supriya Lifescience Ltd | HIT | |
| “Bullish on Supriya Lifescience Ltd., recommending a buy between ₹735-750 with a target price of ₹860 in two to three mon…” | Marketsmith India AnalysisMarketsmith India | Supriya Lifescience Ltd. | MISS | |
| “Bullish on Supriya Lifescience Ltd., recommending a buy at ₹735-750 with a target price of ₹860 in two to three months a…” | Marketsmith India AnalysisMarketsmith India | Supriya Lifescience Ltd. | MISS | |
| “Bullish on Supriya Lifescience, recommending a buy at ₹788 with a target of ₹850 and a stop loss at ₹760. This is part o…” | Sumeet BagadiaChoice Equity Broking | Supriya Lifescience Ltd | MISS | |
| “Bullish on Supriya Lifescience, recommending a buy above ₹762 with a stop loss at ₹735 and targets of ₹820-835. The stoc…” | Raja VenkatramanNeoTrader | Supriya Lifescience Ltd | MISS | |
| “Bullish on Supriya Lifescience, recommending a buy above ₹762 with a stop loss at ₹735 and targets between ₹820-835 for …” | Raja VenkatramanNeoTrader | Supriya Lifescience Ltd | MISS | |
| “Recommends buying SUPRIYA on dips above ₹398, with a stop loss at ₹390 and a target of ₹415. The stock is rebounding fro…” | Raja VenkatramanNeoTrader | SUPRIYA Lifescience Ltd | PENDING |
Fundamentals
About Supriya Lifescience Limited
Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals in India and internationally. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, antihypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides finished formulation products. In addition, the company offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, it develops drugs in the areas of anti-depressant, anti-inflammatory, contrast media, hormones, antibiotic, smoking cessation, anti-diabetic/obesity, anti-ataxia, decongestant, veterinary API, anti-cancer, allogeneic hematopoietic stem cell transplantation, and anti-migraine. Supriya Lifescience Limited was founded in 1987 and is headquartered in Mumbai, India.
Details
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Satish Waman Wagh
Headquarters
Mumbai
Employees
607
Website
supriyalifescience.comExchange
View on NSE ↗Key stats
Market cap
₹6,875.65 Cr
P/E ratio (TTM)
34.4
Dividend yield
0.12%
EPS (TTM)
₹24.81
Beta (1Y · daily vs NIFTY 50)
0.74
Beta (5Y · monthly vs NIFTY 50)
1.05
Shares float
2.55 Cr
EPS · quarter ended Jun 2026
₹2.99
Financial Performance
01 · Financials
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
Total assets for FY22: from the company's own statements, which the series had none for. Current assets for FY22: from the company's own statements, which the series had none for. Equity for FY22: from the company's own statements, which the series had none for. Inventory for FY22: from the company's own statements, which the series had none for. Cash for FY22: from the company's own statements, which the series had none for.
08 · Profit & Loss — as filed
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹470.43 Cr | ₹580.98 Cr | ₹706.30 Cr | ₹839.36 Cr | |
| ₹346.94 Cr | ₹415.29 Cr | ₹457.82 Cr | ₹564.13 Cr | |
Earnings before Tax and exceptional items | ₹123.49 Cr | ₹165.69 Cr | ₹248.48 Cr | ₹275.24 Cr |
(One time impact of New LabourCodes (Refer Note 38)) | — | — | — | ₹-45.80 L |
Profit before tax | ₹123.49 Cr | ₹165.69 Cr | ₹248.48 Cr | ₹274.78 Cr |
| ₹33.63 Cr | ₹46.58 Cr | ₹60.52 Cr | ₹65.66 Cr | |
Profit for the year | ₹89.86 Cr | ₹119.11 Cr | ₹187.96 Cr | ₹209.12 Cr |
| ₹88.60 Cr | ₹120.74 Cr | ₹187.83 Cr | ₹209.02 Cr | |
Basic (₹) | 11.16 | 14.80 | 23.35 | 25.98 |
Diluted (*) | 11.16 | 14.80 | 23.35 | 25.98 |
The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.
All years: standalone statements.
09 · Balance Sheet — as filed
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹355.39 Cr | ₹523.43 Cr | ₹675.28 Cr | ₹824.80 Cr | |
(a) Inventories | ₹115.77 Cr | ₹85.25 Cr | ₹118.35 Cr | ₹159.60 Cr |
(i) Loans and Advances | ₹54.90 L | ₹89.70 L | ₹92.70 L | ₹56.90 L |
(ii) Trade receivables | ₹84.66 Cr | ₹111.68 Cr | ₹134.36 Cr | ₹219.45 Cr |
(iii) Cash and cash equivalents | ₹85.25 Cr | ₹68.35 Cr | ₹76.06 Cr | ₹37.55 Cr |
(iv) Bank balances other than (iii) above | ₹72.33 Cr | ₹6.61 Cr | ₹3.10 Cr | ₹41.32 Cr |
(v) Other Financial Assets | ₹6.41 Cr | ₹4.51 Cr | ₹71.10 L | — |
(c) Other current assets | ₹99.92 Cr | ₹120.72 Cr | ₹108.57 Cr | ₹73.82 Cr |
Total Current Assets | ₹464.89 Cr | ₹398.02 Cr | ₹442.07 Cr | ₹532.30 Cr |
TOTAL ASSETS | ₹820.28 Cr | ₹921.45 Cr | ₹1,117.35 Cr | ₹1,357.11 Cr |
| ₹699.46 Cr | ₹815.37 Cr | ₹996.76 Cr | ₹1,197.73 Cr | |
(i) Borrowings | — | — | ₹5.06 Cr | ₹5.19 Cr |
(ii) Lease Liabilities | ₹5.49 Cr | ₹5.02 Cr | — | — |
(b) Provisions | ₹5.88 Cr | ₹80.40 L | ₹1.32 Cr | ₹1.90 Cr |
(c) Deferred tax Liabilities | ₹13.68 Cr | ₹23.15 Cr | ₹27.02 Cr | ₹31.24 Cr |
Total Non-Current Liabilities | ₹25.04 Cr | ₹28.98 Cr | ₹33.39 Cr | ₹38.33 Cr |
(i) Borrowings | ₹16.63 Cr | — | ₹32.30 L | ₹24.60 L |
(ii) Lease liabilities | ₹35.40 L | ₹46.80 L | — | ₹17.00 Cr |
Other than Micro Enterprises and Small Enterprises | ₹64.23 Cr | ₹59.57 Cr | ₹74.55 Cr | ₹93.85 Cr |
(iii) Other financial liabilities | ₹82.10 L | ₹1.57 Cr | ₹1.76 Cr | ₹2.04 Cr |
(b) Provisions | ₹83.70 L | ₹36.50 L | ₹1.19 Cr | ₹1.67 Cr |
(c) Other current liabilities | ₹12.92 Cr | ₹15.13 Cr | ₹9.37 Cr | ₹6.24 Cr |
Total Current Liabilities | ₹95.78 Cr | ₹77.11 Cr | ₹87.19 Cr | ₹121.04 Cr |
TOTAL EQUITY AND LIABILITIES | ₹820.28 Cr | ₹921.45 Cr | ₹1,117.35 Cr | ₹1,357.11 Cr |
The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.
All years: standalone statements.
10 · Cash Flow Statement — as filed
Annual
| Line item | FY24 | FY25 | FY26 |
|---|---|---|---|
| ₹-82.63 Cr | ₹4.20 Cr | ₹-28.70 L | |
| ₹113.31 Cr | ₹164.68 Cr | ₹185.77 Cr | |
| ₹-173.57 Cr | ₹-152.24 Cr | ₹-176.17 Cr | |
| ₹-22.36 Cr | ₹-8.23 Cr | ₹-9.88 Cr | |
Cash and Cash Equivalents at the end of previous period | ₹157.58 Cr | ₹74.96 Cr | ₹79.15 Cr |
Cash and Cash Equivalents as at the end of the reporting period | ₹74.96 Cr | ₹79.15 Cr | ₹78.87 Cr |
The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.
All years: standalone statements.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Dec 21–Dec 22(6Q) | Mar 23 | Jun 23–Jun 26(13Q) |
|---|---|---|---|
| Promoter | 68.24% | 68.28% | 68.30% |
| Public | 31.76% | 31.72% | 31.70% |
| Employee trusts | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.25 L Cr | ₹1,769.9 | 38.8 | 5.09 | 13.7% | 0.06 | +11.9% | +3.7% |
| Divi's Laboratories Limited | ₹2.66 L Cr | ₹10,037.5 | 90.8 | 15.85 | 15.3% | 0.00 | +12.3% | +47.5% |
| Torrent Pharmaceuticals Limited | ₹1.79 L Cr | ₹4,738.5 | 79.4 | 21.31 | 25.8% | 1.79 | +21.5% | +32.5% |
| Laurus Labs Limited | ₹1.27 L Cr | ₹2,348 | 94.8 | 23.94 | 16.8% | 0.48 | +22.0% | +146.2% |
| Apollo Hospitals Enterprise Limited | ₹1.23 L Cr | ₹8,599.5 | 58.8 | 12.95 | 20.5% | 0.90 | +15.7% | +10.1% |
| Zydus Lifesciences Limited | ₹1.19 L Cr | ₹1,188.1 | 26.7 | 4.40 | 18.6% | 0.46 | +18.4% | +22.3% |
| Lenskart Solutions Limited | ₹1.16 L Cr | ₹689.7 | 181.4 | 13.30 | 5.6% | 0.35 | +35.4% | — |
| Dr. Reddy's Laboratories Limited | ₹1.14 L Cr | ₹1,374 | 40.6 | 3.02 | 11.4% | 0.21 | +3.2% | +14.5% |
| Cipla Limited | ₹1.13 L Cr | ₹1,402 | 38.9 | 3.27 | 11.3% | 0.02 | +2.1% | -6.7% |
| Mankind Pharma Limited | ₹1.03 L Cr | ₹2,475 | 45.9 | 6.31 | 11.7% | 0.39 | +17.0% | +3.1% |
| Aurobindo Pharma Limited | ₹98,101.93 Cr | ₹1,705 | 26.6 | 2.59 | 9.2% | 0.21 | +6.4% | +48.4% |
| Supriya Lifescience Limited | ₹6,724.34 Cr | ₹832.8 | 33.9 | 5.61 | 17.5% | 0.00 | +18.1% | +6.1% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
2 indices
Supriya Lifescience Reports 14.8% Revenue Growth In H1 FY27
Supriya Lifescience Ltd. reported a 14.8% year‑on‑year revenue rise to Rs 396.04 crore in H1 FY27, driven by higher sales in Europe and expanding vitamin and analgesic segments. However, EBITDA and PAT margins fell sharply due to regulatory shifts in Latin America, higher raw‑material costs, and ramp‑up expenses at its Ambernath plant.